DiaMedica Therapeutics Inc. (DMAC)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 130% in DiaMedica Therapeutics (DMAC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy
DiaMedica Therapeutics (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript
DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript
DiaMedica Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 3 | $20 | $19.99 | -$0.01 | -0.05% |
 Leon G. Cooperman Omega Advisors | 3.45M | $22.82M | $23.05M | $227,143.27 | 1% |
 Private Capital Private Capital Management | 50,000 | $343,500 | $334,000 | -$9,500 | -2.77% |
| YA Yinka Akinsola Blue Trust Inc. | 69,122 | $320,466.18 | $438,233.48 | $117,767.3 | 36.75% |
 Joseph Castro Nuveen LLC | 48,349 | $371,791.11 | $321,520.85 | -$50,270.26 | -13.52% |
DiaMedica Therapeutics Inc. (DMAC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has DiaMedica Therapeutics Inc. ever had a stock split?
DiaMedica Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dietrich John Pauls CEO | NASDAQ (CM) Exchange | 25253X207 CUSIP |
| US Country | 35 Employees | - Last Dividend | 15 Nov 2018 Last Split | 4 Jan 2008 IPO Date |
Overview
DiaMedica Therapeutics Inc. is a dynamic clinical stage biopharmaceutical enterprise concentrating on the development of innovative treatments designed to enhance the quality of life for individuals contending with severe diseases, with a particular focus on acute ischemic stroke. The company has honed its expertise towards addressing neurological disorders and cardio-renal diseases, aiming to bridge the gap in current treatment options. Formally known as DiaMedica Inc., the organization underwent a name change in December 2016 to better reflect its evolved focus and expanded therapeutic ambitions. Founded in the year 2000, DiaMedica Therapeutics has established its headquarters in Minneapolis, Minnesota, positioning itself as a pivotal player in the biopharmaceutical industry with its forward-thinking approaches and commitment to pioneering healthcare solutions.
Products and Services
-
DM199:
This is DiaMedica Therapeutics’ flagship product. DM199 is a pharmaceutically active recombinant version of the kallikrein-1 protein, propelling the forefront of the company's innovation. It is currently under development for the treatment of acute ischemic stroke among other vascular diseases. Through its clinical stage trials, DM199 embodies the company's ambition to significantly improve the therapeutic outcomes for patients suffering from vascular-related conditions, leveraging the biological mechanisms of the kallikrein-1 protein to offer hope where conventional treatments might have been inadequate.
-
DM300:
In the exploratory phases of development, DM300 represents DiaMedica Therapeutics’ venture into addressing inflammatory diseases. Though still in its preclinical stages, this initiative underscores the company’s dedication to expanding its portfolio beyond vascular diseases, venturing into new territories of medical need. The development of DM300 aligns with DiaMedica's strategy to harness scientific innovations in pursuit of addressing unmet medical needs across diverse therapeutic areas.
